CSF β-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 30 05 2019
revised: 17 10 2019
accepted: 20 10 2019
pubmed: 2 11 2019
medline: 20 11 2020
entrez: 1 11 2019
Statut: ppublish

Résumé

Neurodegeneration is present from the earliest stages of multiple sclerosis (MS) and is critically involved in MS related clinical disability. Aim of the present study was to assess the connection between amyloid burden and early cerebellar grey matter (GM) atrophy compared to early brain GM atrophy in MS patients. Forty newly diagnosed relapsing-remitting (RR-) MS patients were recruited. β-amyloid1-42 (Aβ) levels were determined in cerebrospinal fluid (CSF) samples from all subjects. All participants underwent neurological examination and brain magnetic resonance imaging (MRI) at baseline. Twenty-nine out of 40 patients repeated a brain MRI at 1-year follow-up. T1-weighted scans were segmented using the Voxel-Based Morphometry (VBM) protocol and the Spatially Unbiased Infratentorial Toolbox (SUIT) from Statistical Parametric Mapping (SPM12). Between-group comparison of cerebellar parenchymal fraction (GM+WM/total cerebellar volume%) showed significant differences between Aβ Early cerebellar atrophy seems to be crucial in predicting a poor prognosis in MS, more than early global brain atrophy.

Sections du résumé

BACKGROUND BACKGROUND
Neurodegeneration is present from the earliest stages of multiple sclerosis (MS) and is critically involved in MS related clinical disability. Aim of the present study was to assess the connection between amyloid burden and early cerebellar grey matter (GM) atrophy compared to early brain GM atrophy in MS patients.
METHODS METHODS
Forty newly diagnosed relapsing-remitting (RR-) MS patients were recruited. β-amyloid1-42 (Aβ) levels were determined in cerebrospinal fluid (CSF) samples from all subjects. All participants underwent neurological examination and brain magnetic resonance imaging (MRI) at baseline. Twenty-nine out of 40 patients repeated a brain MRI at 1-year follow-up. T1-weighted scans were segmented using the Voxel-Based Morphometry (VBM) protocol and the Spatially Unbiased Infratentorial Toolbox (SUIT) from Statistical Parametric Mapping (SPM12).
RESULTS RESULTS
Between-group comparison of cerebellar parenchymal fraction (GM+WM/total cerebellar volume%) showed significant differences between Aβ
CONCLUSIONS CONCLUSIONS
Early cerebellar atrophy seems to be crucial in predicting a poor prognosis in MS, more than early global brain atrophy.

Identifiants

pubmed: 31671315
pii: S2211-0348(19)30451-1
doi: 10.1016/j.msard.2019.101462
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101462

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Auteurs

Anna M Pietroboni (AM)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy. Electronic address: pb.anna@libero.it.

Francesca Schiano di Cola (F)

Neurology Clinic, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Annalisa Colombi (A)

University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy.

Tiziana Carandini (T)

University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy.

Chiara Fenoglio (C)

University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy.

Laura Ghezzi (L)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy.

Milena A De Riz (MA)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy.

Fabio Triulzi (F)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neuroradiology Unit, Milan, Italy.

Elio Scarpini (E)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy.

Alessandro Padovani (A)

Neurology Clinic, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Daniela Galimberti (D)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Milan, Italy; Dino Ferrari Center, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH